Search research articles
Contact Us
Filters
Showing results (51-60 of 86) with videos related to
Page
of 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2010
Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer
Carol M Moinpour, Nancy L Vaught, Bryan Goldman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 7, 2024
Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)
David Kozono, Xing Hua, Michael C Wu, et al.
JAMA Oncology
|
September 10, 2020
Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial
Seth M Pollack, Mary W Redman, Kelsey K Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2023
Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Shirish M Gadgeel, Jieling Miao, Jonathan W Riess, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2020
Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403
Sarah B Goldberg, Mary W Redman, Rogerio Lilenbaum, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 3, 2015
Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer
Nathan R Foster, Lindsay A Renfro, Steven E Schild, et al.
Pancreas
|
October 2, 2023
Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma
Andrew L Coveler, Venu G Pillarisetty, Wui-Jin Koh, et al.
Clinical Lung Cancer
|
February 15, 2021
Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G
Taofeek K Owonikoko, Mary W Redman, Lauren A Byers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2022
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A
Karen L Reckamp, Mary W Redman, Konstantin H Dragnev, et al.
The Lancet. Oncology
|
November 25, 2017
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study
Roy S Herbst, Mary W Redman, Edward S Kim, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 86) with videos related to
Sort By:
Page
of 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2010
Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer
Carol M Moinpour, Nancy L Vaught, Bryan Goldman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 7, 2024
Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)
David Kozono, Xing Hua, Michael C Wu, et al.
JAMA Oncology
|
September 10, 2020
Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial
Seth M Pollack, Mary W Redman, Kelsey K Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2023
Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Shirish M Gadgeel, Jieling Miao, Jonathan W Riess, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2020
Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403
Sarah B Goldberg, Mary W Redman, Rogerio Lilenbaum, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 3, 2015
Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer
Nathan R Foster, Lindsay A Renfro, Steven E Schild, et al.
Pancreas
|
October 2, 2023
Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma
Andrew L Coveler, Venu G Pillarisetty, Wui-Jin Koh, et al.
Clinical Lung Cancer
|
February 15, 2021
Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G
Taofeek K Owonikoko, Mary W Redman, Lauren A Byers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2022
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A
Karen L Reckamp, Mary W Redman, Konstantin H Dragnev, et al.
The Lancet. Oncology
|
November 25, 2017
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study
Roy S Herbst, Mary W Redman, Edward S Kim, et al.
Page
of 9